Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01556282 · ClinicalTrials.gov registry record · NA
TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis
A NA study, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 35
- Enrollment target
NCT01556282: Completed NA study, sponsored by Emory University.
NCT01556282 is a NA study that has completed, run by Emory University. The registered enrollment target is 35 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01556282, a NA study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 35 participants
- Enrollment target
Study Summary
Therasphere will be administered via catheter through the Hepatic Artery to treat patients with Hepatocellular Carcinoma and Portal vein Thrombosis.
Interventions
- DEVICE TheraSphere
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2009-03 |
| Est. Completion | 2014-01 |
| Phase | NA |
What the finished NCT01556282 record still lists
NCT01556282 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which TheraSphere is the first listed.
NCT01556282 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01556282 about?
NCT01556282 is a clinical study titled "TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis". Therasphere will be administered via catheter through the Hepatic Artery to treat patients with Hepatocellular Carcinoma and Portal vein Thrombosis.
What is the current status of trial NCT01556282?
This trial is currently completed. It is a NA study. The enrollment target is 35 participants. The study started on 2009-03. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01556282?
The interventions under investigation include: TheraSphere (DEVICE).
Who is sponsoring clinical trial NCT01556282?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01556282's enrollment target sits among peer trials
35 1564th of 2000 higher than 431 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia